Value-Based Care

Real-world data highlight the significant clinical and economic burden associated with venous thromboembolism (VTE) in patients with cancer. The data come from a study of 12,785 patients hospitalized with acute illnesses, of which 2002 patients had cancer. Read More ›

An analysis of real-world administrative claims data in patients with chronic lymphocytic leukemia (CLL) has highlighted the need for treatments that result in fewer adverse events, according to data presented at ASH 2018. Read More ›

The drug affordability rating in the National Comprehensive Cancer Network (NCCN) Evidence Blocks are inconsistent with real-world total episode of care costs, according to Scott D. Ramsey, MD, PhD, Director, Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA. Read More ›

“It’s the disease of not listening that I am troubled with,” a quote attributed to King Henry IV, kicked off a spirited panel discussion on the importance of incorporating the patient’s voice during treatment. Experts addressed these challenges at the 2018 Association of Community Cancer Centers Annual Meeting & Cancer Center Business Summit on March 16, 2018, in Washington, DC. Read More ›

As the cost of cancer care continues to rise, greater transparency throughout the process of drug pricing and drug payment needs to become part of the clinical discussion, said Leonard Saltz, MD, Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. Read More ›

With cancer care costs on the rise, attaining value-based care—curbing costs while maintaining or improving the quality of care—is becoming a high priority. Alternative payment models are increasingly holding practices accountable for the quality of care that they provide, as well as their use of resources, by requiring that practices report on various quality measures. Read More ›

The cost of cancer drugs has increased exponentially over the past decade, straining the healthcare system and patients’ ability to pay for them. Pharmaceutical manufacturers continue to increase drug prices through packaging maneuvers and the use of artificial expiration dates, and as a result, some old drugs “in new clothing” remain expensive. Read More ›

The November 2016 presidential elections have cast a shadow in many minds about the future of the transition from the volume-driven, fee-for-service healthcare delivery model to the value-based care model. With the current promises of repealing and replacing the Affordable Care Act (ACA) of 2010, physicians and healthcare providers are left guessing as to what they will be expected to do, and where their future is heading. Read More ›

With the advent of a shift to value-based care and increasing accountability for effective care, patient engagement is emerging as the primary mechanism to effect change. However, the sheer volume of patients means that physicians and nurses cannot hope to touch them every day in the meaningful ways needed to fully engage each patient. Read More ›

Value frameworks in oncology are relatively early in development, and their ultimate impact remains unknown, but at a minimum, providers should be aware of the current value frameworks and how each value framework measures value, as well as their implications for clinical trial development, said Kasia Shields, PharmD, MBA, BCOP, BCPS, Director, Medical Communications, Xcenda/AmerisourceBergen, at the 2016 Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program. Read More ›

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: